All lobbying filings

INSULET CORPORATION

INSULET CORPORATION filed a Q1 report for INSULET CORPORATION on April 17, 2025.

Lobbying for INSULET CORPORATION

All filings by INSULET CORPORATION · Everything INSULET CORPORATION has reported

Filing · LD-2 quarterly report Q1 report

Reporting period

1st Quarter 2025

Jan 1 - Mar 31 · Posted Apr 17, 2025

Expenses

$40,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

Massachusetts

Official filing document

Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Health Issues

Issues related to the disease of diabetes, diabetes therapies, automated insulin delivery devices, and management of the disease of diabetes. Issues related to medical devices and medical device technologies. Issues related to Pharmacy Benefit Manager (PBM) reform proposals, PBM transparency and potential PBM proposals related to budget reconciliation package. Issues related to the reintroduction or possible reintroduction of the DIABETES Act in the 119th Congress. Issues related to artificial intelligence (AI) and predictive algorithms in medical devices and medical device technology. Issues related to tariffs and trade. Issues related to Local Coverage Determination revisions specifically in pathways for Continuous Glucose Monitors (CGM).

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.